Aanjaneya Lifecare is currently trading at Rs. 732.50, up by 30.90 points or 4.40% from its previous closing of Rs. 701.60 on the BSE.
The scrip opened at Rs. 700.00 and has touched a high and low of Rs. 738.85 and Rs. 695.00 respectively. So far 11125 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 810.00 on 27-Nov-2012 and a 52 week low of Rs. 360.85 on 10-May-2012.
Last one week high and low of the scrip stood at Rs. 762.00 and Rs. 675.45 respectively. The current market cap of the company is Rs. 1014.66 crore.
The promoters holding in the company stood at 47.58% while Institutions and Non-Institutions held 0.27% and 52.15% respectively.
Aanjaneya Lifecare has been conferred with ‘Asia’s Emerging Pharmaceutical Company on Innovations Award 2013’ at Assocham’s 10th Knowledge Millennium Summit. The award was organized by The Associated Chambers of Commerce and Industry of India (ASSOCHAM) where by The Department of Science & Technology, Ministry of Science & Technology Government of India was one of the partner organization.
Aanjaneya Lifecare is a leading research based integrated pharmaceutical company with established research, manufacturing and marketing capabilities. It is R&D focused, has a multi product portfolio with state of the art manufacturing facilities, and is set to become a marketing conglomerate across the globe. It has a WHO GMP approved facilities for manufacturing bulk drugs at Mahad and finished dosage forms at Pirungut near Pune.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: